Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 2.9 per share [5] Core Views - The company reported H1 2024 revenue of HKD 2,402.5 million, a slight decrease of 0.1% YoY, while net profit attributable to shareholders increased by 0.4% YoY to HKD 304.5 million [2] - Gross margin improved by 0.4 percentage points to 26.4% in H1 2024 [2] - The aerospace sector showed strong growth, with revenue increasing by 35.3% YoY, driven by global market recovery and new product launches [2] - Traditional industrial sectors faced pressure, with engineering machinery revenue down 16.9%, agricultural machinery down 14.0%, and leisure marine & vehicle revenue down 25.9% [2] - The company's new factories in Mexico are fully operational, with 3 expected to break even by end-2024 and 2 aerospace and surface treatment facilities to start mass production in H2 2025 [2] - The company's global diversification strategy is paying off, with aerospace and medical equipment sectors expected to become new growth drivers [2] Financial Performance - Revenue is projected to grow at a CAGR of 8.7% from 2024E to 2026E, reaching HKD 5,980 million by 2026E [4] - Net profit attributable to shareholders is expected to grow from HKD 613 million in 2024E to HKD 786 million in 2026E, representing a CAGR of 13.2% [4] - EPS is forecasted to increase from HKD 0.32 in 2024E to HKD 0.42 in 2026E [4] - ROE is expected to remain stable at around 11.2%-11.5% from 2024E to 2026E [4] Strategic Developments - The company's global diversification strategy is mitigating market cyclical risks, with aerospace and medical equipment sectors poised to become new growth engines [2] - The company is accelerating capacity expansion in Mexico to address tariff risks, with 5 new factories already completed in H1 2024 [2] - The US market accounted for 45.4% of total revenue in H1 2024, with Mexico contributing 10% of total capacity in 2023 [2]
鹰普精密：重压之下业绩维稳，海外放量未来可期